Loading...
XTAI
1707
Market cap615mUSD
Dec 05, Last price  
130.00TWD
1D
0.39%
1Q
0.39%
Jan 2017
-30.48%
Name

Grape King Bio Ltd

Chart & Performance

D1W1MN
XTAI:1707 chart
P/E
13.30
P/S
1.73
EPS
9.78
Div Yield, %
5.31%
Shrs. gr., 5y
1.78%
Rev. gr., 5y
3.85%
Revenues
11.16b
+4.93%
1,489,681,0001,702,107,0002,112,457,0002,821,859,0003,282,274,0003,771,021,0004,611,719,0005,652,413,0006,282,859,0007,247,855,0009,185,021,0009,388,128,0009,183,321,0009,239,070,0009,168,195,0009,798,246,00010,391,231,00010,635,464,00011,160,005,000
Net income
1.45b
-0.30%
150,422,000180,871,000164,522,000379,341,000427,700,000473,062,000618,902,000835,762,000942,483,0001,051,652,0001,296,769,0001,351,941,0001,295,394,0001,938,566,0001,895,095,0001,947,989,0002,169,687,0001,452,728,0001,448,299,000
CFO
1.88b
-25.54%
468,842,000253,111,000434,852,000720,611,000683,894,000848,526,0001,121,257,0001,575,779,0001,701,422,0001,306,930,0002,803,128,0002,495,656,0002,417,429,0002,171,439,0002,719,190,0002,542,204,0002,990,437,0002,519,402,0001,875,912,000
Dividend
Jun 23, 20254.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes. It also provides OEM, ODM, formulation design, research and development, and raw material supply services. The company was founded in 1969 and is headquartered in Taoyuan City, Taiwan.
URL
https://www.grapeking.com.tw/
IPO date
Dec 20, 1982
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT